7th March 2008 - Orexo's licensing partner for Rapinyl in Europe, ProStrakan Group plc announces that Rapinyl™ has received Swedish Marketing Authorization. It is anticipated that the product branded as "Abstral" will be launched in Sweden in Q3 2008 through Orexo's joint venture with ProStrakan, which operates in the Nordic countries.
Rapinyl™ is a fast-dissolving tablet for sublingual administration of fentanyl intended for the treatment of breakthrough cancer pain, for which ProStrakan Group plc, the international specialty pharmaceutical company, has in-licensed exclusive rights in Europe from Orexo. ProStrakan today announces that it has received Marketing Authorization in Sweden for Rapinyl™.
No comments:
Post a Comment